BioCentury | Sep 17, 2019
Financial News

Bayer invests $20M in One Drop's digital platform

As digital health's footprint continues to grow, Bayer is leading One Drop's $40 million series B round and licensing its diabetes self-management platform for use in other disease areas. Bayer AG (Xetra:BAYN) said Tuesday it...
BioCentury | Apr 13, 2018
Financial News

Rothschild becomes Andera after employee, partner buyout

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...
BioCentury | Apr 6, 2018
Financial News

Partners, employees buy out Rothschilds' stake in EdRIP

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...
BioCentury | Jun 3, 2016
Financial News

LSP closes fifth fund at $280 million

LSP closed its fifth fund, LSP 5, at a hard cap of $280 million, well above its initial target of $170 million. The firm plans to invest LSP 5 with the same strategy as previous...
BioCentury | Sep 30, 2013
Company News

GlaxoSmithKline, Merck, Pfizer, Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, German Ministry for Economic Cooperation and Development

JPMorgan and the Gates Foundation formed the Global Health Investment Fund (GHIF) to support late stage development of technologies against diseases that disproportionately burden low-income countries. With $94 million in committed capital from individual and...
BioCentury | Sep 24, 2013
Financial News

JPMorgan and Gates Foundation form $94M global health fund

JPMorgan and the Bill & Melinda Gates Foundation formed the Global Health Investment Fund (GHIF) to support late stage development of technologies against diseases that disproportionately burden low-income countries. With $94 million in committed capital...
BioCentury | May 6, 2013
Financial News

Capital Royalty L.P. financial update

Capital Royalty closed its second private equity fund, Capital Royalty Partners II, at $805 million. The firm invests worldwide in approved and commercialized healthcare products and technologies through a variety of structures including secured debt...
BioCentury | May 3, 2013
Financial News

Capital Royalty closes $805M fund

Capital Royalty closed its second private equity fund, Capital Royalty Partners II, at $805 million. The firm invests worldwide in approved and commercialized healthcare products and technologies through a variety of structures including secured debt...
BioCentury | Nov 10, 2008
Finance

The denominator effect

Some of the largest public pension funds, crushed by losses in the public equity markets, are being forced to either reassess how they allocate their investments or rebalance their portfolios in order to maintain mandated...
BioCentury | Jun 9, 2008
Finance

Ebb & Flow

Having gotten his hands on 215 pages of documents from Biogen Idec (NASDAQ:BIIB) under judicial order by the Delaware Chancery Court, activist investor Carl Icahn last week leveled new charges that at least one potential...
Items per page:
1 - 10 of 13
BioCentury | Sep 17, 2019
Financial News

Bayer invests $20M in One Drop's digital platform

As digital health's footprint continues to grow, Bayer is leading One Drop's $40 million series B round and licensing its diabetes self-management platform for use in other disease areas. Bayer AG (Xetra:BAYN) said Tuesday it...
BioCentury | Apr 13, 2018
Financial News

Rothschild becomes Andera after employee, partner buyout

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...
BioCentury | Apr 6, 2018
Financial News

Partners, employees buy out Rothschilds' stake in EdRIP

Edmond de Rothschild Investment Partners said the firm's partners and employees bought out the Rothschild family office's 51% majority stake, making the firm independent. The firm changed its name to Andera Partners, but said its...
BioCentury | Jun 3, 2016
Financial News

LSP closes fifth fund at $280 million

LSP closed its fifth fund, LSP 5, at a hard cap of $280 million, well above its initial target of $170 million. The firm plans to invest LSP 5 with the same strategy as previous...
BioCentury | Sep 30, 2013
Company News

GlaxoSmithKline, Merck, Pfizer, Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, German Ministry for Economic Cooperation and Development

JPMorgan and the Gates Foundation formed the Global Health Investment Fund (GHIF) to support late stage development of technologies against diseases that disproportionately burden low-income countries. With $94 million in committed capital from individual and...
BioCentury | Sep 24, 2013
Financial News

JPMorgan and Gates Foundation form $94M global health fund

JPMorgan and the Bill & Melinda Gates Foundation formed the Global Health Investment Fund (GHIF) to support late stage development of technologies against diseases that disproportionately burden low-income countries. With $94 million in committed capital...
BioCentury | May 6, 2013
Financial News

Capital Royalty L.P. financial update

Capital Royalty closed its second private equity fund, Capital Royalty Partners II, at $805 million. The firm invests worldwide in approved and commercialized healthcare products and technologies through a variety of structures including secured debt...
BioCentury | May 3, 2013
Financial News

Capital Royalty closes $805M fund

Capital Royalty closed its second private equity fund, Capital Royalty Partners II, at $805 million. The firm invests worldwide in approved and commercialized healthcare products and technologies through a variety of structures including secured debt...
BioCentury | Nov 10, 2008
Finance

The denominator effect

Some of the largest public pension funds, crushed by losses in the public equity markets, are being forced to either reassess how they allocate their investments or rebalance their portfolios in order to maintain mandated...
BioCentury | Jun 9, 2008
Finance

Ebb & Flow

Having gotten his hands on 215 pages of documents from Biogen Idec (NASDAQ:BIIB) under judicial order by the Delaware Chancery Court, activist investor Carl Icahn last week leveled new charges that at least one potential...
Items per page:
1 - 10 of 13